Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2018/V15/I1/63

[1] 王少兵. 注射用吲哚菁绿致过敏性休克1例[J]. 中国药物警戒,2014,11(4):248-249.
[2] William C,Avinash C,Robert T,et al.Anaphylactic shock after intravenous administration of indocyanine green during robotic partial nephrectomy[J]. Urology Case Reports,2017,12(5):37-38.
[3] 于倩,郭义明,崔海珍,等. 吲哚菁绿排泄试验与肝脏储备功能的相关性评价[J].中国实验诊断学,2014,18(11):1776-1778.
[4] 董家鸿,郑树森,陈孝平,等. 肝切除术前肝脏储备功能评估的专家共识(2011版)[J].中华消化外科杂志,2011,10(1):20-25.
[5] 李博,高蕊,李睿,等.药物临床试验不良反应/不良事件关联性判定方法研究探索[J].中国新药杂志,2014,23(12):1465-1470.
[6] 王雪丽,徐敏芬,陈红,等.吲哚菁绿在肝储备功能检测中不良反应的护理体会[J]. 海峡药学,2011,23(5):262-263.
[7] 胡滨,臧娴,陈娟娟,等.肝储备功能检测中吲哚菁绿不良反应的预防及处理[J]. 按摩与康复医学,2012,3(11):82-83.
[8] Bjerregaard J,Pandia M P,Jaffe R A.Occurrence of severe hypotension after indocyanine green injection during the intraoperative period[J]. A A Case Reports,2013,1(1) :26-30.
[9] Hope-Ross M,Yannuzzi L A,Gragoudas E S,et al.Adverse reactions due to indocyanine green[J]. Ophthalmology,1994,101(3):529-533.
[10] 张茂姬,罗敏. 醋酸泼尼松片和注射用氢化可的松琥珀酸钠致过敏反应1 例[J]. 中国药物警戒,2017,14(4):255-256.
[11] 梁晓雯,杨友林,陈蕾. 碘造影剂的过敏反应及防范措施[J]. 山西医药,2013,42(6):700-701.
[12] 杨旭,黄晓青,华潞,等. 52例冠状动脉造影患者非离子含碘对比剂过敏不良反应分析[J]. 中国循环杂志,2015,30(8):741-743.
[13] 娄莹,徐波,杨跃进,等. 非离子型冠脉造影剂致急性严重过敏样反应的病例分析[J].中国药物警戒,2010,7(5):281-284 .
[14] 梁瑶,孙路路. 碘造影剂对过敏样反应发生机制研究进展及防治[J]. 临床药物治疗杂志,2016,14(3):6-10.

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics